Recurrent and refractory angina following revascularization procedures in patients with stable angina pectoris

Coronary Artery Disease

Volumn 15, Issue SUPPL. 1, 2004, Pages

  Thadani, Udho ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NITRATE; RANOLAZINE; TRIMETAZIDINE;

CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; EDITORIAL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MORBIDITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; RESTENOSIS; SMOKING CESSATION; STABLE ANGINA PECTORIS; SURGICAL MORTALITY;

ANGINA PECTORIS; ANGIOPLASTY, BALLOON; CORONARY ARTERY BYPASS; HUMANS; MYOCARDIAL REVASCULARIZATION; RECURRENCE; STENTS;

EID: 3042711321     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mca.0000129883.86374.6c     Document Type: Editorial

References (50)

1. Thadani U, Fung HL, Darke AL, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose response relationship during acute and sustained therapy. Am J Cardiol 1982; 49:411-419.
2. De Mots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cordiol 1989; 13:786-792.
3. Thadani U, Lipicky RJ. Short and long acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994; 8:611-623.
4. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 1994; 8:625-633.
5. Thadani U, Davidson C, Simpleton W, Taylor SH. Comparison of the immediate effects of five beta adrenoceptor blocking drugs with different ancillary properties in angina pectoris. N Engl J Med 1979; 300:750-755.
6. Opie LH, Sonnenblick EH, Frishman W, Thadani U. Beta blocking agents. In: Opie LH (editor): Drugs for the Heart. Philadelphia: WB Saunders; 1995, pp. 1-27.
7. Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 1996; 38:273-290.
8. Thadani U. Selective L-type, and non-selective calcium channel blockers for stable angina pectoris [Editorial]. Am Heart J 2002; 144:8-10.
9. Thadani U, Glasser S, Bittar N, Beach C and the Diltiazem CD Study Group. Dose-response evaluation of once-daily therapy with a new formulation of diltiazem for stable angina pectoris. Am J Cardiol 1994; 74:9-17.
10. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, Held C, et al. Effect of metoprolol versus verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J 1996; 17:76-81.
11. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281:1927-1936.
12. Dargie HJ, Ford I, Fox KM, on behalf of the TIBET Study Group. Effects of ischemia and treatment with atenolol, nifedipine SR and their combination on outcomes in patient with chronic stable angina. Eur Heart J 1996; 17:104-112.
13. Akhras F, Jackson A. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991; 338:1036-1039.
14. Thadani U. Management of stable angina pectoris. Prog Cardiovasc Dis 1999; 14:349-358.
15. Thadani U. The pursuit of optimum outcomes in stable angina. Am J Cardiovasc Drugs 2003; 3(suppl 1):11-20.
16. Task Force of the European Society of Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18:394-413.
17. Canadian Cardiovascular Society. 1997 Consensus Conference on the Evaluation and Management of Chronic Ischemic Heart Disease. Can J Cardiol 1998; 14(suppl C):1c-23c.
18. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA/ACP-ASIM Guideline update for the management of patients with chronic stable angina: summary and abstract. Circulation 2003; 107:149-158.
19. Doll R, Peto R. Mortality in relation to smoking: 20-year observations on British doctors. Br Med J 1976; 2:1526-2536.
20. SAPAT (Swedish Angina Pectoris Aspirin Trial) Group, Juul-Moller S, Edvardson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340:1421-1425.
21. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
22. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high risk individuals. A randomized placebo controlled trial. Lancet 2003; 36:7-22.
23. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, et al. Effect of coronary artery bypass graft surgery on survival: overview often year results from randomized trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 1994; 344:563-570.
24. Peduzzi P, Kamina A, Detre K, for the VA Coronary Artery Bypass Surgery Cooperative Study Group. Twenty-two-year follow-up in the VA cooperative study of coronary artery bypass surgery for stable angina. Am J Cardiol 1998; 81:1393-1399.
25. Hartigan PM, Giacomini JC, Folland ED, Parisi A, for VA Cooperative Studies Program ACME Investigators. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Am J Cardiol 1998; 82:1445-1450.
26. Chaitman BR, Rosen AD, Williams DO, Bourassa MG, Aguirre FV, Pitt B, et al. Myocardial infarction and cardiac mortality in the bypass angioplasty revascularization investigation (BARI) randomized trial. Circulation 1997; 96:2162-2170.
27. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the prevention of restenosis with Tranilast and its outcomes (PRESTO) trial. Circulation 2004; 109:476-480.
28. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, et al. For the randomized intervention treatment of angina trial participants. Seven-year outcome in the RITA -2 trial. Coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42:1167-1170.
29. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341:70-76.
30. King SR III. Dilate or defer? View of a skeptic. J Am Coll Cardiol 2003; 42:1171-1172.
31. Hambrecht R, Walther C, Mobius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease. Circulation 2004; 109:1371-1378.
32. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with standard stent for coronary revascularization. N Eng J Med 2002; 346:1773-1780.
33. Mosses JW, Leon MB, Pompa JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with a native coronary artery. N Engl J Med 2003; 349:1315-1323.
34. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. For the E-SIRUS sirolimus-eluting stents for the treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRUS). Lancet 2003; 362:1093-1099.
35. Ellis S, Stone W, Pompa JF, Weissman N, Hermiller J, Cox DA, et al. The TAXUS IV study: final angiographic results [Abstract no. 2429]. Circulation 2003; 108(suppl 4):532.
36. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization or sirolimus-eluting stents compared with conventional bare stents implantation in the "real world" the rapamycin eluting stents evaluated at Rotterdam Cardiology Hospital (Research) Registry. Circulation 2004; 109:190-195.
37. Faxon DP. Bringing reality to drug-coated stents. Circulation 2004; 109:140-142.
38. Kim MC, Kini A, Sharma SK. Refractory angina pectoris. J Am Coll Cardiol 2002; 39:923-934.
39. Thadani U. Patient with disabling angina not amenable to revascularization procedures in acute coronary syndromes: a comparison to Braunwald's heart disease. Acute Coronary Syndromes. In: Theroux P (editor): Saunders; 2003, pp. 539-552.
40. Levy S, Manchanda SC, Krishnaswani S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 76:353-357.
41. Michaelides AP, Vyssoulis GP, Bonoris PB. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Therapeut Res 1989; 46:1179-1190.
42. Sellier P, Brounstet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris. A multicenter, double blind, placebo controlled study. Am J Cardiovasc Drugs 2003; 3:361-369.
43. Thadani U, Ezekowitz M, Fenney L, Chiang YK. Double-blind efficacy and safety study of a novel anti-ischemic agnet, ranolazine, versus placebo in patients with chronic stable angina pectoris; Ranolazine Study Group. Circulation 1994; 90:726-734.
44. Wolff AA for the MARISA Study Group. Monotherapy assessment of ranolazine in stable angina [Abstract]. J Am Coll Cardiol 2000; 35(suppl A):408A.1
45. Chaitman B, Pepine J, Parker JO for the CLARISA Study Group. Effects of ranolazine with atenolol, amlodipine or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 2004; 291:309-316.
46. Arora R, Chou T, Jain D, Fleishman B, Crawford L, McKiernan T, Nesto RW. The Multicenter Study of Enhanced External CounterPulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol 1999; 33:1833-1840.
47. Lawson WE, Hui JC, Cohn PF. Long-term prognosis of patients with angina treatment with enhanced external counterpulsation: five-year follow-up study. Clin Cardiol 2000; 23:254-258.
48. Mannheimer C, Augustinsson LE, Eliasson T. Spinal cord stimulation in severe angina pectoris. Reduced ischemia and increased quality of life. Lakartidningen 1994; 91:3257-3261.
49. Mannheimer C, Eliasson T, Augustinsson LE, Blomstrand C, Emanuelsson H, Larsson S, et al. Electrical stimulation versus coronary artery bypass surgery is severe angina pectoris: the ESBY study. Circulation 1998; 97:1157-1163.
50. Szwed H, Sadowski Z, Epikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double blind, multicenter study (TRIMPOL II). Eur Heart J 2001; 22:2267-2274.